ZURICH (Reuters) - Swiss biotech group Basilea has clinched "orphan" drug status from U.S. health authorities for antifungal treatment isavuconazole, progress on a product that analysts estimate could be worth up to 150 million francs an...
Source: http://health.yahoo.net/news/s/nm/basilea-antifungal-wins-coveted-u-s-drug-status
home homepage view homepage homepage here
No comments:
Post a Comment
Note: only a member of this blog may post a comment.